Atrial fibrillation (AF) is the most frequent arrhythmia seen in clinical practice. The incidence of persistent and permanent AF will likely continue to increase as the population ages and as patients with structural heart disease live longer. Until recently, antiarrhythmic medications have been the only commonly employed treatment for maintaining sinus rhythm. However, antiarrhythmic medications have a modest long-term efficacy and the potential for serious side effects. Radiofrequency (RF) catheter ablation is now emerging as a viable alternative to antiarrhythmic medications in maintaining sinus rhythm in patients with AF. A number of different ablation strategies have been used including pulmonary vein isolation, targeting of fractionated electrograms, compartmentalising the atria with linear lesions and various combinations and modifications of these lesion sets. The variation in success within and between techniques suggests that the optimal ablation technique for AF is unclear. The general consensus for patients with paroxysmal atrial fibrillation is to achieve electrical isolation of the pulmonary veins (PVs). In patients with non-paroxysmal AF, PV isolation alone appears to be insufficient. In addition, the structural and electrophysiological changes that have typically occurred at the advanced stage of AF lend greater importance to the identification and ablation of atrial myocardial substrate-driven "sources". Further efforts are needed to develop better techniques and tools to safely, effectively, and permanently isolate the pulmonary veins, to identify which sites are critical to the maintenance of AF, and to create durable lesions to interrupt intra-arterial reentry. In this review, the rationale and outcomes of rhythm management with drugs and ablation strategies targeting various mechanisms of AF based on our current understanding are discussed.
INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, accounting for approximately one-third of hospitalisations for cardiac rhythm disturbances. Atrial fibrillation affects 1-2% of the population, and this figure is likely to increase in the next 50 years 1, 2 . Over 6 million Europeans suffer from this arrhythmia, and its prevalence is estimated to at least double in the next 50 years as the population ages. The currently diagnosed estimate of 2.3 million people in the United States with it is expected to increase to 5.6 million by 2050.
The prevalence of AF increases with age, from 0.5% at 40-50 years, to 5-15% at 80 years [1] [2] [3] [4] [5] . Men are more often affected than women. The lifetime risk of developing AF is 25% in those who have reached the age of 40 6 . Cardiovascular Health Study and Framingham Study data indicate that the incidence of AF per 1000 person-years in those younger than the age 64 years is 3.1 in men and 1.9 in women, increasing sharply to approximately 19.2 per 1000 person-years in those aged 65 to 74 years and to as high as 31.4 to 38 in octogenarians 7, 8 .
Death rates are doubled by AF, independently of other known predictors of mortality 9, 10 . Atrial fibrillation confers a 5-fold risk of stroke, and one in five of all strokes is attributed to this arrhythmia. Left ventricular function is often impaired by the irregular, fast ventricular rate and by loss of atrial contractile function and increased end-diastolic LV Proceedings of Singapore Healthcare  Volume 24  Number 1  2015 rapid in the first year after initial diagnosis (8.6%) and then rises more slowly to 24.7% by 5 years.
Several studies investigating AF progression have been published in the past [13] [14] [15] [16] . The rate of AF progression described in these studies varied between 8% and 22% after 1 year of follow-up, depending on the rhythm-monitoring methods used. Various factors were associated with AF progression: valvular disease, alcohol consumption, age, left atrial dimension and amount of atrial enlargement over time, stroke, and heart failure 17 .
ANTIARRHYTHMIC DRUGS VS CATHETER ABLATION
Although a strategy for rhythm control with antiarrhythmic drugs or electrical cardioversion offers no survival advantage over a rate control strategy, retrospective analyses of major trials show that maintenance of sinus rhythm may be associated with improved survival and quality of life 18, 19 . In the Atrial Fibrillation follow-up investigation of rhythm management (AFFIRM) trial, non-cardiovascular deaths in the rhythm control arm exceeded those in the rate control arm 20 , fuelling speculation that adverse effects of antiarrhythmic drugs may obscure the benefits of maintaining sinus rhythm and justifying the comparison of catheter ablation with medical therapy for achievement of sinus rhythm.
In a pilot trial of 70 patients with predominantly paroxysmal atrial fibrillation (in 96%), pulmonary vein isolation was compared with antiarrhythmic drugs (Flecainide in 77 and Sotalol in 23) as first line therapy 21 . Freedom from symptomatic atrial fibrillation at one year after a single procedure was 87% compared with 37% for patients treated with antiarrhythmic drugs, most of whom received Flecainide. In another study, pulmonary vein isolation (circumferential pulmonary vein ablation) in conjunction with antiarrhythmic drugs was compared with antiarrhythmic drugs (various combinations of Amiodarone, Flecainide, Propafenone and Sotalol) in a group of 137 patients with mostly paroxysmal atrial fibrillation (67% paroxysmal, 33% persistent) 22 . Freedom from atrial arrhythmias at one year was 56% in the ablation with antiarrhythmic drugs group and only 9% in the antiarrhythmic drugs alone group. In another study a group of 198 patients with paroxysmal atrial fibrillation 23 pulmonary vein isolation (circumferential pulmonary vein ablation) was superior to a pharmacological strategy filling pressure. Patients with AF have a significantly poorer quality of life compared with healthy controls, the general population, or patients with coronary heart disease in sinus rhythm 11 .
CLINICAL CLASSIFICATION
Clinically, it is reasonable to distinguish five types of AF based on the presentation and duration of the arrhythmia:
(1) Every patient who presents with AF for the first time is considered a patient with first diagnosed AF, irrespective of the duration of the arrhythmia or the presence and severity of AF-related symptoms.
(2) Paroxysmal AF is self-terminating, usually within 48 h. Although AF paroxysms may continue for up to 7 days, the 48 h time point is clinically importantafter this the likelihood of spontaneous conversion is low and anticoagulation must be considered.
(3) Persistent AF is present when an AF episode either lasts longer than 7 days or requires termination by cardioversion, either with drugs or by direct current cardioversion (DCC).
(4) Long-standing persistent AF has lasted for ≥1 year when it is decided to adopt a rhythm control strategy.
(5) Permanent AF is said to exist when the presence of the arrhythmia is accepted by the patient (and physician). Hence, rhythm control interventions are, by definition, not pursued in patients with permanent AF. Should a rhythm control strategy be adopted, the arrhythmia is redesignated as 'longstanding persistent AF' .
COURSE AND PROGRESSION
Once AF has manifested, it is usually a chronically progressing arrhythmia. The presence of AF, especially of long periods of the arrhythmia, causes pronounced electrical and structural alterations in the atria, thereby promoting its recurrence and progression from paroxysmal to chronic AF. In addition, chronic underlying comorbidities, a genetic predisposition to AF, and 'natural' ageing processes remodel the atria and contribute to the initiation and progression of AF.
The Canadian Registry of Atrial Fibrillation (CARAF) 12 provides a unique opportunity to follow the patients presenting with paroxysmal AF. The CARAF has demonstrated that progression to chronic AF is most Review Proceedings of Singapore Healthcare  Volume 24  Number 1  2015 consisting of Flecainide, Sotalol, or Amiodarone. Daily transtelephonic monitoring and periodic Holter monitoring showed that freedom from atrial tachyarrhythmias at one year was 86% in the ablation group and 22% in the antiarrhythmic drug group. The success of ablation improved to 93% when including second procedures.
A recent meta-analysis 24 (including 69.8% patients with paroxysmal AF in ablation group and 56.4% in antiarrhythmic group) found overall success rate of 77% for catheter ablation and 52% for antiarrhythmic medication. The single-procedure success rate of ablation off antiarrhythmic drug (AAD) therapy was 57%, the multiple procedure success rate off AAD was 71%, and the multiple procedure success rate on AAD or with unknown AAD usage was 77%. In comparison, the success rate for AAD therapy was 52%. A major complication of catheter ablation occurred in 4.9% of patients. Adverse events for AAD studies, were although more common (30%), but less severe.
In the ThermoCool trial 25 , a randomised multicentre study of 167 symptomatic patients with paroxysmal AF who had not shown improvement with at least one antiarrhythmic drug, radiofrequency catheter ablation with pulmonary vein isolation resulted in significantly fewer episodes of recurrent AF than did treatment with additional antiarrhythmic drugs. Repeat catheter ablation procedures were performed in 12.6% of the ablation group. Ultimately, 34% of ablation patients had recurrence of symptomatic AF during the 9-month follow-up period, compared with 84% of the drug-treated group. In this highly selected patient population, in patients for whom one antiarrhythmic drug has failed, subsequent antiarrhythmic drug treatment is likely to fail; such patients may benefit from catheter ablation.
The catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation (CABANA) trial will assess survival outcomes among patients treated with ablation compared with those treated with pharmacological rhythm or rate control drugs. The multicentre radiofrequency ablation versus antiarrhythmic drugs for atrial fibrillation treatment (RAAFT) trial will compare catheter ablation as first line therapy against antiarrhythmic drugs.
The catheter ablation for the cure of atrial fibrillation (CACAF-2) study will compare the efficacy of catheter ablation with combined right and left atrial lesions against antiarrhythmic drugs in patients with persistent atrial fibrillation refractory to at least one antiarrhythmic drug.
CURRENT CATHETER ABLATION TECHNIQUES AND OUTCOMES
Based on the seminal observation by Haissaguerre et al. 26 that premature depolarisation from the myocardial sleeves that extend into the PVs trigger AF, initial attempts primarily targeted arrhythmogenic activity within the PVs 27 .
As a result pulmonary vein stenosis may be associated with this procedure, techniques emerged that attempted to isolate the left atrium from the pulmonary veins. Predominant approaches included segmental ostial ablation at sites where pulmonary vein signals were detected 28 , and anatomically guided circumferential pulmonary vein ablation encircling individual or ipsilateral pairs of pulmonary veins 29 .
The procedural endpoint for pulmonary vein Isolation is achievement of permanent electrical isolation of the pulmonary veins, which in the vast majority of patients harbour triggered electrical activity inducing and maintaining AF. However, it is now evident that persistent or long-standing persistent AF may not be successfully treated by PV isolation alone since the majority of patients have AF maintaining substrate beyond the pulmonary veins. From a pathophysiological perspective this is explained by structural and electrical remodelling of the atrial myocardium in patients with persistent AF. Therefore, it is today widely accepted that additional substrate modification is required to effectively address persistent AF using catheter ablation. So the current catheter ablation strategies for AF fall into two broad categories:
Pulmonary Vein Isolation
Isolation of the PVs remains the backbone of most AF catheter ablation procedures. Isolation of the pulmonary veins can be performed with circumferential PV ablation (CPVA), encircling around the septal (right) pulmonary veins and another lesion around the lateral (left) pulmonary veins. Several variations of this approach have been developed, reaching from ostial ablation of the pulmonary veins ('Segmental ostial isolation') to more atrial-sided, 'antral' ablation.
Circumferential PV ablation (CPVA), involves
Proceedings of Singapore Healthcare  Volume 24  Number 1  2015 applications of radiofrequency energy 1-2 cm away from the ostia of the PVs, except along the rim between the left-sided PVs and left atrial appendage 30 . A key aspect of CPVA is elimination of all residual potentials within the encircling lesion sets. A number of ablation strategies have been described with variations in the technique, including wide area circumferential ablation, left atrial circumferential ablation, and CPVA with confirmation of PV isolation using multipolar ring catheters 31, 32 . However, the premise of all of these strategies is ablation of a wide area around the PVs that extends well beyond the tubular portion of the PV (Fig. 1 ).
Antral PV isolation (APVI) that targets all potentials within the PV antrum with an end-point of complete electrical isolation of the PVs has been reported to have a high efficacy both in patients with paroxysmal and in those with persistent AF 33 . Pulmonary vein antrum may also harbor the high-frequency sources or rotors, which are thought to have anchor points around the PV ostia 34 . In addition, ganglionated plexi that have been implicated in the genesis of AF often are located with the PV antrum [35] [36] [37] . Therefore, APVI may eliminate a number of potential mechanisms of AF, including PV and antral arrhythmogenicity, highfrequency sources, non-PV ectopy, and ablation of ganglionated plexi. Furthermore, a considerable amount of atrial debulking (25-30%) may occur after APVI, with a reduction in the wavelength available for potential reentrant drivers 38 . Therefore, APVI has become a preferred ablation strategy in patients with paroxysmal and persistent AF (Fig. 2) .
Pulmonary vein isolation can be achieved by segmental ostial ablation guided by PV potentials 28 . There are isolated fascicles that travel from the left atrium into the muscle sleeves that surround the pulmonary veins and that radiofrequency ablation of these fascicles, as opposed to circumferential ablation at the ostium, is sufficient to isolate the veins. Pulmonary veins are electrically disconnected from the left atrium by targeting only certain segments of the ostial circumference, as guided by pulmonary vein potentials.
Beyond Pulmonary Vein Isolation
To further improve the efficacy of catheter ablation, several studies investigated how to identify residual drivers of AF that may not necessarily be eliminated by pulmonary vein isolation.
(A) Electrogram guided ablation
Complex fractionated atrial electrograms (CFAEs) have been described as fractionated electrograms composed of two or more deflections, electrograms with a continuous perturbation of the baseline or prolonged low-voltage activation, or electrograms with a very short cycle length (<120 ms). It has been suggested that CFAEs may indicate sites of slow conduction, wavefront collision, conduction block, or anchor points for reentrant circuits. A prior study reported that ablation of CFAEs without routine PV isolation was associated with freedom from AF in approximately 90% of patients with paroxysmal or persistent AF 39 . In a subsequent study, CFAEs were targeted in patients with persistent AF without PV isolation. Sinus rhythm was maintained in 33% of the patients after one ablation and in 65% after repeat procedures 40 .
Studies have suggested that a preponderance of CFAE sites exist in close proximity to the PVs or sites of autonomic ganglionated plexi 41 and, therefore, substantial overlap may exist between CFAE targeted lesion sets and other ablation strategies.
(B) Linear lesions
In an attempt to recapitulate the early success of surgically placed linear ablation lesions, a number of catheter-based linear lesions have been advocated to improve long-term success rates. Linear lesions along the roof of the left atrium connecting the superior aspects of the left and right upper PV isolation lesions ("roof" line) and linear lesions along the region between the mitral annulus and the left inferior PV (Mitral isthmus) may improve clinical outcomes 42 .
(C) Autonomic denervation
Areas rich in autonomic innervation may be a source of activity that triggers AF. Damage to ganglionated plexi, usually located 1-2 cm outside of the PV ostia, has been proposed as an effect of antral PV ablation 43 .
(D) Stepwise ablation approach
In most patients, multiple mechanisms likely contribute to the initiation and perpetuation of AF. Therefore, tailored approaches combining more than one ablation technique have been described. Using combined approaches, the extent of left atrial ablation has been advocated as a marker of longterm success and as an adjunctive procedural end point.
The stepwise approach requires several key ablation techniques, namely, PV isolation, Linear ablation at the roof and mitral isthmus, Electro gram-targeted ablation, and discretionary right atrial ablation (superior vena cava, intercaval, or cavo-tricuspid isthmus lines). Each region is targeted in sequence. A number of stepwise or tailored approaches have implemented increasing ablation lesions until AF is rendered noninducible 44 .
How Safe is Catheter Ablation?
Recent large international survey 45 on the methods, efficacy, and safety of catheter ablation of atrial fibrillation from 182 centres including 16,309 patients reported the overall incidence of major complications 4.5%. Tamponade was the most frequent complication (1.31%). Others were femoral pseudoaneurysm (0.93%), PV stenosis requiring intervention (0.29%), Stroke (0.23%), Atriumesophageal fistula (0.04%) and Death (0.15%). In addition, new onset atypical atrial flutter was observed in 8.6%.
Real World Experience
However, most of the data on AF ablation comes from clinical trials in highly selective populations. These centres are usually high volume centres with skilled operators. Are their results reproducible in the real world settings? Do we have real world data? Shah et al. 46 studied 4,156 AF ablation cases in the Healthcare Utilization Project California State Inpatient Database to provide a more realistic picture of complication rates in contemporary practice. The study found that 5% of patients undergoing an initial AF ablation had a complication, and 9% of patients had to be readmitted to the hospital within 30 days of their AF ablation. Older age, female sex, and prior AF hospitalisations were the patient factors associated with higher risk of complications and 30-day readmission. Less hospital experience with AF ablation was also associated with a higher adjusted risk of complications and/or 30-day readmissions.
Fortunately, most of the complications were not severe. The most common complications were vascular, usually bleeding. Of those who had complications, about 44% developed a haematoma or haemorrhage, and 49.3% had a perforation or tamponade. Only one death and 10 strokes were related to procedural complications.
The first worldwide, multicentre survey on catheter ablation 47 was published using data from 181 centres from 1995-2002. Of those who underwent AF ablation, 52% of these patients were successful and symptom-free without antiarrhythmic drugs. An additional 23.9% were symptomatic and AF-free with antiarrhythmic drugs, which was previously ineffective. Twenty-four point three per cent of Proceedings of Singapore Healthcare  Volume 24  Number 1  2015 patients underwent a second procedure and 3.1% underwent a third procedure for 3.1%. As anticipated, success rates were highest in high-volume centres.
The second worldwide multicentre survey 45 , on catheter ablations performed from 2003-2006, has subsequently been published and showed an improvement in treatment success. The success rate was 70% without antiarrhythmic drugs and increased to 80% if patients were maintained on antiarrhythmic drugs. The success rates without antiarrhythmic drugs were 75% for those with paroxysmal AF, 65% for persistent AF and 63% for longstanding persistent AF.
The long term success rates for AF ablation was reported by Ouyang et al 48 . In 161 patients who underwent circumferential PV isolation for symptomatic paroxysmal AF in 2003 to 2004, stable sinus rhythm was achieved in 79.5% of patients during a median follow-up of 4.6 years. Of note, 66 patients required a second procedure while 12 patients required a third procedure.
Of those patients who required repeat procedures, pulmonary vein electrical reconnection were the most common observation. In some patients, extrapulmonary vein triggers were seen and these were targeted for ablation. In patients who underwent linear ablation, electrical recovery with gaps seen along these linear ablation were seen. As such, catheter ablation has produced less than ideal success rates. These results speak of the complexity of treating patients with AF.
Oral Anticoagulants After Catheter Ablation
What should we do about oral anticoagulants in patients who seemingly have had a successful cure of their atrial fibrillation? The desire, of course, is to be able to safely terminate oral anticoagulants. However, several practice patterns have emerged based on the apparent presence or absence of atrial fibrillation, duration of recurrent episodes, and stroke risk stratification, (CHADS2 score). The recommendations as per ACC/AHA guidelines are:
1. Warfarin is recommended for all patients for at least 2 months after an AF ablation procedure.
2. Decisions regarding the use of warfarin more than 2 months after ablation should be based on the patient risk factors for stroke and not on the presence or type of AF.
3. Discontinuation of warfarin therapy postablation is generally not recommended in patients who have a CHADS2 score ≥2.
CONCLUSION
Atrial fibrillation is the most common arrhythmia in clinical practice. In suitable patients, catheter ablation to restore sinus rhythm appears to be a more suitable strategy than anti-arrhythmic drugs. Patients with paroxysmal atrial fibrillation tend to respond better than those with persistent atrial fibrillation. Pulmonary vein isolation remains the cornerstone of AF ablation. The role of adjunctive ablation to improve the clinical outcome of AF ablation remains controversial.
